Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 21.686 (Stand 1. Dezember 2022) 
Amgevita® (Adalimumab)162
Benepali® (Etanercept)1007
Cimzia® (Certolizumab)993
Enbrel® (Etanercept)2870
Erelzi® (Etanercept)430
Flixabi® (Infliximab)10
Hulio® (Adalimumab)162
Humira® (Adalimumab)2904
Hyrimoz® (Adalimumab)152
Idacio® (Adalimumab)44
Imraldi® (Adalimumab)156
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)86
Kevzara® (Sarilumab)184
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)33
Olumiant® (Baricitinib)508
Orencia® (Abatacept)926
Remicade® (Infliximab)762
Remsima® (Infliximab)15
Rinvoq® (Upadacitinib)263
Rixathon® (Rituximab)19
RoActemra® (Tocilizumab)1338
Ruxience® (Rituximab)1
Simponi® (Golimumab)454
Xeljanz® (Tofacitinib)387
Zessly® (Infliximab)2
Kontrollen6254